

# Avadel Pharmaceuticals plc Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

<https://marketpublishers.com/r/F2908AEA712BEN.html>

Date: May 2025

Pages: 50

Price: US\$ 499.00 (Single User License)

ID: F2908AEA712BEN

## Abstracts

Avadel Pharmaceuticals plc Fundamental Company Report provides a complete overview of the company's affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Avadel Pharmaceuticals plc and its competitors. This provides our Clients with a clear understanding of Avadel Pharmaceuticals plc position in the [Pharmaceuticals and Biotechnology](#) Industry.

The report contains detailed information about Avadel Pharmaceuticals plc that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.

Another part of the report is a SWOT-analysis carried out for Avadel Pharmaceuticals plc. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company's strengths, weaknesses, opportunities, and possible threats against it.

The Avadel Pharmaceuticals plc financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios

pertaining to profitability, margin analysis, asset turnover, credit ratios, and company's long-term solvency. This sort of company's information will assist and strengthen your company's decision-making processes.

In the part that describes Avadel Pharmaceuticals plc competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company's competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company's business and sales activities will be boosted by gaining an insight into your competitors' businesses.

Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Avadel Pharmaceuticals plc business.

## **About Avadel Pharmaceuticals plc**

Flamel Technologies S.A., a biopharmaceutical company, engages in the development of polymer-based drug delivery technologies for the improvement of medical applications.

The company's nanoparticle Medusa technology is designed to provide controlled release following injection of therapeutic proteins, peptides and other large and small molecules. It also developed a microparticle adaptation of the Medusa platform. Its Micropump technology is a multiparticle technology for oral administration of small molecule drugs with applications in controlled-release, taste-masking, and bioavailability enhancement.

### **Products Based on the Micropump Technology**

The company's approved product using the Micropump platform is Coreg CR, which it developed with GlaxoSmithKline (GSK).

**Coreg CR:** Coreg CR is an extended-release formulation of Coreg (carvedilol phosphate), a beta blocker that is considered the standard of care for the treatment of

moderate to severe heart failure and left ventricular dysfunction following myocardial infarction.

Coreg and Coreg CR are indicated for the treatment of congestive heart failure (CHF), as well as for the treatment of left ventricular dysfunction following myocardial infarction. Coreg and Coreg CR additionally are indicated for the treatment of hypertension. Coreg is part of the standard of care for the treatment of heart failure. Coreg and Coreg CR are the beta blockers indicated for the severe form of heart failure. Carvedilol is a non-selective antagonist of Beta 1, Beta 2 and adrenergic receptors, and a selective antagonist of Alpha 1 adrenergic receptors.

#### Other Products under Development Based on Micropump Technology

The company conducted Micropump feasibility studies on other proprietary therapeutic compounds under limited agreements with the pharmaceutical companies owning the rights to these compounds. It engages in two such projects, one for a liquid formulation of an already-marketed over-the-counter product and a second for a combination product in the cardiovascular setting.

#### Strategic Alliances

**Baxter International, Inc.:** In 2009, the company entered into collaboration with Baxter International Inc. to create controlled release applications of blood clotting factor replacement therapies using its Medusa technology. This collaboration includes work on intravenous formulations.

**Merck Serono:** The company has a relationship with Merck Serono to develop a controlled release formulation of an already-marketed Merck Serono product using its Medusa technology platform. In 2009, Merck Serono exercised its option to a development and license agreement for this program.

**Pfizer:** The company works with Pfizer to assess the applicability of the Medusa platform to certain molecules in development. In 2009, Pfizer exercised its option to license the Medusa technology for the development of a controlled release formulation of an already-marketed protein.

**Corning: Photochromic Materials:** Corning S.A and Corning Incorporated (Corning) has an agreement with the company for the co-development of proprietary, polymer-based photochromic eyeglass lens material to be sold by Corning to manufacturers of

ophthalmic lenses worldwide.

## History

Flamel Technologies S.A. was founded in 1990.

The above Company Fundamental Report is a half-ready report and contents are subject to change.

It means that we have all necessary data in our database to prepare the report but need **2-3 days** to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

## Contents

RESEARCH METHODOLOGY

DISCLAIMER

### **1. AVADEL PHARMACEUTICALS PLC COMPANY PROFILE**

- 1.1. Key facts
- 1.2. Financial Performance
- 1.3. Key Executives
- 1.4. Ownership and Major Holders
- 1.5. Company History

### **2. AVADEL PHARMACEUTICALS PLC BUSINESS OVERVIEW**

- 2.1. Business Description
- 2.2. Major Products and Services
- 2.3. Markets and Sales Activities
- 2.4. Locations, Subsidiaries, Operating Units

### **3. AVADEL PHARMACEUTICALS PLC SWOT ANALYSIS**

- 3.1. Overview
- 3.2. Strengths
- 3.3. Weaknesses
- 3.4. Opportunities
- 3.5. Threats

### **4. AVADEL PHARMACEUTICALS PLC FINANCIAL ANALYSIS**

- 4.1. Financial Statements
  - 4.1.1. Income Statement
  - 4.1.2. Balance Sheet
  - 4.1.3. Cash Flow
- 4.2. Financial Ratios
  - 4.2.1. Profitability
  - 4.2.2. Margin Analysis

- 4.2.3. Asset Turnover
- 4.2.4. Credit Ratios
- 4.2.5. Long-Term Solvency
- 4.2.6. Growth Over Prior Year
- 4.2.7. Financial Ratios Charts
- 4.3. Stock Market Snapshot

## **5. AVADEL PHARMACEUTICALS PLC COMPETITORS AND INDUSTRY ANALYSIS**

- 5.1. Avadel Pharmaceuticals plc Direct Competitors
- 5.2. Comparison of Avadel Pharmaceuticals plc and Direct Competitors Financial Ratios
- 5.3. Comparison of Avadel Pharmaceuticals plc and Direct Competitors Stock Charts
- 5.4. Avadel Pharmaceuticals plc Industry Analysis
  - 5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  - 5.4.2. Avadel Pharmaceuticals plc Industry Position Analysis

## **6. AVADEL PHARMACEUTICALS PLC NEWS & EVENTS**

- 6.1. News & PR Activity Analysis
- 6.2. IR Corporate News
- 6.3. Marketing News
- 6.4. Corporate Events

## **7. AVADEL PHARMACEUTICALS PLC EXPERTS REVIEW<sup>1</sup>**

- 7.1. Experts Consensus
- 7.2. Experts Revisions

## **8. AVADEL PHARMACEUTICALS PLC ENHANCED SWOT ANALYSIS<sup>2</sup>**

## **9. FRANCE PESTEL ANALYSIS<sup>2</sup>**

- 9.1. Political Factors
- 9.2. Economic Factors
- 9.3. Social Factors
- 9.4. Technological Factors
- 9.5. Environmental Factors
- 9.6. Legal Factors

## **10. AVADEL PHARMACEUTICALS PLC IFE, EFE, IE MATRICES<sup>2</sup>**

- 10.1. Internal Factor Evaluation Matrix
- 10.2. External Factor Evaluation Matrix
- 10.3. Internal External Matrix

## **11. AVADEL PHARMACEUTICALS PLC PORTER FIVE FORCES ANALYSIS<sup>2</sup>**

## **12. AVADEL PHARMACEUTICALS PLC VRIO ANALYSIS<sup>2</sup>**

### **APPENDIX: RATIO DEFINITIONS**

### **LIST OF FIGURES**

Avadel Pharmaceuticals plc Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit  
Profit Margin Chart  
Operating Margin Chart  
Return on Equity (ROE) Chart  
Return on Assets (ROA) Chart  
Debt to Equity Chart  
Current Ratio Chart  
Avadel Pharmaceuticals plc 1-year Stock Charts  
Avadel Pharmaceuticals plc 5-year Stock Charts  
Avadel Pharmaceuticals plc vs. Main Indexes 1-year Stock Chart  
Avadel Pharmaceuticals plc vs. Direct Competitors 1-year Stock Charts  
Avadel Pharmaceuticals plc Article Density Chart

1 – Data availability depends on company's security policy.

2 – These sections are available only when you purchase a report with appropriate additional types of analyses.  
The complete financial data is available for publicly traded companies.

## List Of Tables

### LIST OF TABLES

Avadel Pharmaceuticals plc Key Facts  
Profitability  
Management Effectiveness  
Income Statement Key Figures  
Balance Sheet Key Figures  
Cash Flow Statement Key Figures  
Financial Performance Abbreviation Guide  
Avadel Pharmaceuticals plc Key Executives  
Avadel Pharmaceuticals plc Major Shareholders  
Avadel Pharmaceuticals plc History  
Avadel Pharmaceuticals plc Products  
Revenues by Segment  
Revenues by Region  
Avadel Pharmaceuticals plc Offices and Representations  
Avadel Pharmaceuticals plc SWOT Analysis  
Yearly Income Statement Including Trends  
Income Statement Latest 4 Quarters Including Trends  
Yearly Balance Sheet Including Trends  
Balance Sheet Latest 4 Quarters Including Trends  
Yearly Cash Flow Including Trends  
Cash Flow Latest 4 Quarters Including Trends  
Avadel Pharmaceuticals plc Profitability Ratios  
Margin Analysis Ratios  
Asset Turnover Ratios  
Credit Ratios  
Long-Term Solvency Ratios  
Financial Ratios Growth Over Prior Year  
Avadel Pharmaceuticals plc Capital Market Snapshot  
Avadel Pharmaceuticals plc Direct Competitors Key Facts  
Direct Competitors Profitability Ratios  
Direct Competitors Margin Analysis Ratios  
Direct Competitors Asset Turnover Ratios  
Direct Competitors Credit Ratios  
Direct Competitors Long-Term Solvency Ratios  
Pharmaceuticals and Biotechnology Industry Statistics



Avadel Pharmaceuticals plc Industry Position  
Company vs. Industry Income Statement Analysis  
Company vs. Industry Balance Sheet Analysis  
Company vs. Industry Cash Flow Analysis  
Company vs. Industry Ratios Comparison  
Avadel Pharmaceuticals plc Consensus Recommendations<sup>1</sup>  
Analyst Recommendation Summary<sup>1</sup>  
Price Target Summary<sup>1</sup>  
Experts Recommendation Trends<sup>1</sup>  
Revenue Estimates Analysis<sup>1</sup>  
Earnings Estimates Analysis<sup>1</sup>  
Historical Surprises<sup>1</sup>  
Revenue Estimates Trend<sup>1</sup>  
Earnings Estimates Trend<sup>1</sup>  
Revenue Revisions<sup>1</sup>

## ANALYSIS FEATURES

### SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

### Enhanced SWOT Analysis

Enhanced SWOT is a 3x3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

How to use the strengths to take advantage of the opportunities?

How to use the strengths to reduce likelihood and impact of the threats?

How to overcome the weaknesses that obstruct taking advantage of the opportunities?

How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

### PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

### Key Factors Examined by PESTEL Analysis:

**Political** – What opportunities and pressures are brought by political bodies and what is the degree of public regulations' impact on the business?

**Economic** – What economic policies, trends and structures are expected to affect the organization, what is this influence's degree?

**Sociological** – What cultural and societal aspects will work upon the demand for the business's products and operations?

**Technological** – What impact do the technological aspects, innovations, incentives and barriers have on the organization?

**Environmental** – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?

**Legal** – What laws and legislation will exert influence on the style the business is carried out?

### **IFE, EFE, IE Matrices**

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business's functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors

integrated into one suggestive model.

## **Porter Five Forces Analysis**

The Porter's five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

What composes a threat of substitute products and services?

Is there a threat of new competitors entering the market?

What is the intensity of competitive rivalry?

How big is the bargaining power of buyers?

How significant is the bargaining power of suppliers?

## **VRIO Analysis**

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company's resources and capabilities and bring them together into one aggregate table that includes:

Tangible resources

Financial

Physical

Technological

Organizational

Intangible resources

Human

Innovation and Creativity

## Reputation

### Organizational capabilities

The result of the analysis gives a clear picture of company's competitive and economic implications, answering the questions if the resources mentioned above are:

Valuable?

Rare?

Costly to imitate?

Organized properly?

## I would like to order

Product name: Avadel Pharmaceuticals plc Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Product link: <https://marketpublishers.com/r/F2908AEA712BEN.html>

Price: US\$ 499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F2908AEA712BEN.html>